Comparative Pharmacology
Head-to-head clinical analysis: AZELEX versus PLIAGLIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELEX versus PLIAGLIS.
AZELEX vs PLIAGLIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelaic acid inhibits microbial protein synthesis and reduces the proliferation of Propionibacterium acnes. It also normalizes keratinization and has anti-inflammatory effects by scavenging free radicals.
Pliaglis is a topical local anesthetic combination of lidocaine and tetracaine. Lidocaine and tetracaine stabilize neuronal membranes by inhibiting sodium ion influx, thereby blocking initiation and conduction of nerve impulses.
Apply a thin layer to affected areas twice daily (morning and evening) or as directed by a physician. Topical use only.
Lidocaine 2.5% and prilocaine 2.5% cream: Apply 1 g per 10 cm² of intact skin; cover with occlusive dressing. Maximum dose: 20 g per application for adults weighing ≥70 kg; for <70 kg, max 10 g. Frequency: Single application, minimum 1 hour before procedure, up to 5 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function; prolonged to 3-4 hours in renal impairment.
1.5-2 hours (lidocaine); prolonged in hepatic impairment or heart failure (up to 6-8 hours).
Primarily renal (~60% as unchanged drug and metabolites) and biliary/fecal (~40%).
Renal: 70% (lidocaine and metabolites); fecal: 10% (primarily unchanged); biliary: 20% (metabolites).
Category C
Category C
Topical Acne Agent
Topical Acne Agent